Diazo Biotin-PEG3-alkyne

CAS No. 1884349-58-9

Diazo Biotin-PEG3-alkyne( —— )

Catalog No. M33339 CAS No. 1884349-58-9

Diazo Biotin-PEG3-alkyne is a polyethylene glycol (PEG)-based linker designed specifically for the synthesis of proteolysis-targeting chimeras (PROTACs) .

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 167 In Stock
10MG 275 In Stock
25MG 465 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Diazo Biotin-PEG3-alkyne
  • Note
    Research use only, not for human use.
  • Brief Description
    Diazo Biotin-PEG3-alkyne is a polyethylene glycol (PEG)-based linker designed specifically for the synthesis of proteolysis-targeting chimeras (PROTACs) .
  • Description
    Diazo Biotin-PEG3-alkyne is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. Diazo Biotin-PEG3-alkyne is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
  • In Vitro
    PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    PROTACs
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1884349-58-9
  • Formula Weight
    795.95
  • Molecular Formula
    C39H53N7O9S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C(CCCC(NCCOCCOCCOCCNC(=O)C1=CC=C(N=NC2=CC(CCNC(CCOCC#C)=O)=CC=C2O)C=C1)=O)[C@H]3[C@@]4([C@](CS3)(NC(=O)N4)[H])[H]
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562?
molnova catalog
related products